发明申请
WO2012053768A3 ARYLOXYPHENOXYACETYL-BASED COMPOUND HAVING HIF-1 INHIBITION ACTIVITY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT
审中-公开
基本信息:
- 专利标题： ARYLOXYPHENOXYACETYL-BASED COMPOUND HAVING HIF-1 INHIBITION ACTIVITY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT
- 专利标题（中）：具有HIF-1抑制活性的含有芳基氧基乙酰基的化合物，其制备方法和含有其作为活性成分的药物组合物
- 申请号：PCT/KR2011007589 申请日：2011-10-12
- 公开(公告)号：WO2012053768A3 公开(公告)日：2012-06-21
- 发明人： WON MI-SUN , KIM HWAN-MOOK , LEE KYEONG , PARK SONG-KYU , LEE KI-HO , LEE CHANG-WOO , LEE JUNG-JOON , CHUNG KYUNG-SOOK , KIM BO-KYUNG , JIN YING-LAN
- 申请人： KOREA RES INST OF BIOSCIENCE , UNIV DONGGUK IND ACAD COOP , WON MI-SUN , KIM HWAN-MOOK , LEE KYEONG , PARK SONG-KYU , LEE KI-HO , LEE CHANG-WOO , LEE JUNG-JOON , CHUNG KYUNG-SOOK , KIM BO-KYUNG , JIN YING-LAN
- 专利权人： KOREA RES INST OF BIOSCIENCE,UNIV DONGGUK IND ACAD COOP,WON MI-SUN,KIM HWAN-MOOK,LEE KYEONG,PARK SONG-KYU,LEE KI-HO,LEE CHANG-WOO,LEE JUNG-JOON,CHUNG KYUNG-SOOK,KIM BO-KYUNG,JIN YING-LAN
- 当前专利权人： KOREA RES INST OF BIOSCIENCE,UNIV DONGGUK IND ACAD COOP,WON MI-SUN,KIM HWAN-MOOK,LEE KYEONG,PARK SONG-KYU,LEE KI-HO,LEE CHANG-WOO,LEE JUNG-JOON,CHUNG KYUNG-SOOK,KIM BO-KYUNG,JIN YING-LAN
- 优先权： KR20100102662 2010-10-20
- 主分类号： C07C235/38
- IPC分类号： C07C235/38 ; A61K31/167 ; A61P35/00 ; C07C231/02
摘要：
Disclosed are a compound inhibitory of HIF-1 activity, a method for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound has anticancer activity which is attributable to its inhibitory activity against HIF-1, but not to non-selective cellular toxicity. Thus, having inhibitory activity against HIF-1, the compound or a pharmaceutically acceptable salt thereof can be used as an ingredient in an anticancer agent for various cancers including large intestine cancer, hepatic cancer, stomach cancer and breast cancer. Further, the compound or a pharmaceutically acceptable salt thereof is applicable to the treatment of diabetic retinopathy or arthritis which is aggravated upon the activation of VEGFA by HIF-1.
摘要（中）：
公开了HIF-1活性的化合物抑制剂，其制备方法，以及含有该化合物作为活性成分的药物组合物。 该化合物具有抗癌活性，其归因于其对HIF-1的抑制活性，但不归因于非选择性细胞毒性。 因此，对于HIF-1具有抑制活性，该化合物或其药学上可接受的盐可用作各种癌症，包括大肠癌，肝癌，胃癌和乳腺癌的抗癌剂中的成分。 此外，化合物或其药学上可接受的盐适用于治疗通过HIF-1激活VEGFA时加重的糖尿病性视网膜病变或关节炎。
IPC结构图谱:
| C | 化学；冶金 |
| --C07 | 有机化学 |
| ----C07C | 无环或碳环化合物 |
| ------C07C235/00 | 羧酸酰胺，酸部分的碳架进一步被氧原子取代 |
| --------C07C235/02 | .带有连接在非环碳原子上的羧酰胺基的碳原子和连接在同一碳架上的单键氧原子 |
| ----------C07C235/32 | ..碳架含有六元芳环 |
| ------------C07C235/38 | ...至少1个羧酰胺基的氮原子连接在六元芳环碳原子上 |